Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 ...

AHSCT resets the immune system in highly active RRMS after high-efficacy drugs fail, delivering higher NEDA, fewer relapses, and durable function gains. When high-efficacy drugs stop holding relapsing ...

Epcoritamab shows high rates of first-line response and MRD negativity in older patients with chemo-ineligible DLBCL, whether used alone or with R-mini-CHOP. Current sickle cell disease (SCD) trial ...

A 12-week prospective cohort enrolled 73 patients with guideline-based asthma or COPD and no speech-affecting comorbidities, ...

The FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor for lowering low-density lipoprotein ...

This study examines how key players in managed care drive postacute home health referrals, identifying tensions, limited ...

Deepak Bhatt, MD, MPH, MBA, discusses hot new topics reshaping care for diabetes, obesity, and cardiovascular disease. One example of this new era is the SURPASS-CVOT trial (NCT04255433), a ...

Analyses spanning 35,245 patients across 13 scenarios found comparable initiation of any systemic therapy in Medicare ...

Facility charges exceeded professional fees in variability for 25 of 26 services, with median facility interquartile ratios 2.56 versus 1.78 for professional prices ...

Propensity-matched comparisons across 11 Kaiser Permanente Southern California service areas showed similar 30-day composite ...

Gedatolisib is the first approved agent to inhibit class I PI3K isoforms plus both mTOR complexes, addressing a long-standing challenge in comprehensive PI3K/AKT/mTOR pathway blockade. The indication ...

A rebate-driven formulary model allegedly incentivized higher insulin list prices, affecting three PBMs controlling roughly ...